Business Wire Feed
Zelis Recognized as a 2026 Great Place to Work® in the U.S. and India
Certification in consecutive years reflects Zelis’ continued investment in culture, professional growth, and associate wellbeingBOSTON--(BUSINESS WIRE)--Zelis, a leading provider of healthcare technology solutions, is certified as a Great Place to Work® in both the United more...
HealthNet and AndHealth Celebrate Pharmacy Ribbon Cutting at Barrington Location, Improving Medication Access Across Central Indiana
INDIANAPOLIS, Ind.--(BUSINESS WIRE)--HealthNet and AndHealth celebrated the ribbon cutting of the newly opened HealthNet Pharmacy this week, marking a major investment in affordable pharmacy access, integrated specialty care, and medication support services for patients across more...
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia more...
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 more...
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration of earlier ropeginterferon alfa-2b use in high-risk ET following hydroxyurea intolerance or resistance First presentation more...
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Daiichi Sankyo and AstraZeneca’s Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with an unprecedented median overall survival of approximately two years based on the more...
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRIGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain more...
ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--#5hmC--ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect® Pancreatic Cancer Test at the 2026 more...
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
TOKYO--(BUSINESS WIRE)--Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who more...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Opinion granted based on positive event-free survival, overall survival and pathologic complete response rate results from the Phase 3 KEYNOTE-905 trial If approved, this combination would become the first and only PD-1 inhibitor plus antibody-drug more...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive Opinion Marks a Significant Step Towards Introducing a Crucial First-line Treatment more...
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce more...
Boys & Girls Clubs of America Expands Trauma-Informed Approach to Advance Youth Mental Wellness Nationwide
The organization and its partners are expanding access to trusted adults, safe spaces, and trauma-informed support to help millions of kids and teens build resilience and thriveATLANTA--(BUSINESS WIRE)--As conversations around mental health take center stage more...
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare population over three yearsCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today more...
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities more...
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancer Phase III data from SERENA-6, DESTINY-Breast09 and TROPION-Breast02 span all three major subtypes of metastatic breast cancer CARES Phase more...
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) Annual more...
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026
MORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCO2026--SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of more...
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion more...
Kaname Capital Renews Demand for Independent Third-Party Investigation at Fukuda Denshi; Sets May 29 Deadline Ahead of June 26 AGM
BOSTON--(BUSINESS WIRE)--Kaname Capital, L.P. ("Kaname Capital") today released an open letter to the Board of Directors and Audit & Supervisory Board of Fukuda Denshi Co., Ltd. (TSE: 6960; "Fukuda Denshi"), renewing our demand for the more...
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
ZUG, Switzerland--(BUSINESS WIRE)--Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain more...
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized CareSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VCYT #ASCO26--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, more...
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscapeAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for more...
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy Durable responses, Treg reduction and increased CD8/Treg ratio support imneskibart’s differentiated IL-2 mechanism more...
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released more...